U.S. Auto Stock News

NasdaqGS:KSPI
NasdaqGS:KSPIConsumer Finance

Kaspi.kz’s Biometric Push and Mixed Results Might Change The Case For Investing In Kaspi.kz (KSPI)

Kaspi.kz has reported past fourth-quarter 2025 results, with revenue of KZT 1,145,548 million up from KZT 730,351 million a year earlier, while net income eased to KZT 276,983 million from KZT 316,401 million. Alongside this, the company is pushing new payment technology such as its Kaspi Alakan ‘Pay by Palm’ biometric system and reiterating its focus on value-added services and the Hepsiburada integration. We’ll now examine how Kaspi.kz’s strong revenue growth alongside its Kaspi Alakan...
NasdaqGS:CAKE
NasdaqGS:CAKEHospitality

How Rising Sales But Softer Earnings And Higher Payouts At Cheesecake Factory (CAKE) Has Changed Its Investment Story

The Cheesecake Factory reported past fourth-quarter 2025 sales of US$961.56 million versus US$920.96 million a year earlier, while net income fell to US$28.78 million from US$41.15 million, and full-year 2025 sales rose to US$3.75 billion as net income eased to US$148.43 million from US$156.78 million. Alongside these mixed results, the company raised its quarterly cash dividend to US$0.30 per share and continued repurchasing stock, indicating an ongoing commitment to returning capital to...
NasdaqGS:STRA
NasdaqGS:STRAConsumer Services

Strategic Education (STRA) Is Up 9.8% After AI-Driven Profitability Jump And Capital Returns Update - Has The Bull Case Changed?

In late February 2026, Strategic Education, Inc. reported fourth-quarter 2025 results showing revenue of US$323.21 million and net income of US$37.91 million, alongside a quarterly dividend of US$0.60 per share and completion of a long-running share repurchase authorization. The company’s earnings per share rose meaningfully year on year and were aided by AI-enabled productivity gains and strong growth in its higher-margin Education Technology Services segment, which together improved...
NYSE:RLJ
NYSE:RLJHotel and Resort REITs

A Look At RLJ Lodging Trust (RLJ) Valuation After Strong Q4 Results And Continued Capital Returns

RLJ Lodging Trust (RLJ) shares are in focus after the company posted above-consensus fourth quarter results, highlighting stronger urban hotel performance, higher non-room revenue, active property conversions, and increased balance sheet flexibility from recent refinancing. See our latest analysis for RLJ Lodging Trust. At a share price of US$8.02, RLJ Lodging Trust has seen short term momentum pick up, with a 30 day share price return of 7.94% and a 90 day gain of 8.23%. This comes even...
NasdaqGS:GTM
NasdaqGS:GTMInteractive Media and Services

What ZoomInfo Technologies (GTM)'s AI Pivot and $1 Billion Buyback Plan Means For Shareholders

In recent days, ZoomInfo Technologies reported that its upmarket customers now account for 74% of its business, Copilot AI has reached 20% of annual contract value, and the company approved an additional US$1.00 billion for share repurchases while providing cautious 2026 revenue guidance. At the same time, supportive comments from Nvidia CEO Jensen Huang about AI complementing enterprise software reframed how investors view ZoomInfo’s AI-focused evolution. We’ll now examine how Nvidia’s...
NYSE:DV
NYSE:DVMedia

A Look At DoubleVerify Holdings (DV) Valuation After Record US$300 Million Share Buyback Announcement

DoubleVerify Holdings (DV) has drawn fresh attention after unveiling a record US$300 million share repurchase program, even as its latest results showed softer revenue and earnings alongside moderate guidance for 2026. See our latest analysis for DoubleVerify Holdings. The buyback news arrived after a weak stretch, with the share price return down around 3% year to date and the 1 year total shareholder return down about 29%. However, the stock has bounced sharply in the last week as investors...
NasdaqGS:OPCH
NasdaqGS:OPCHHealthcare

Option Care Health (OPCH) Valuation After 2025 Results And Expanded Share Repurchase Program

Option Care Health (OPCH) shares came into focus after the company reported fourth quarter and full year 2025 results, combining higher sales with margin pressure from biosimilar adoption, reaffirmed guidance and a larger share repurchase program. See our latest analysis for Option Care Health. At a share price of US$32.46, Option Care Health has seen pressure recently, with a 7 day share price return of a 10.06% decline and a 1 month share price return of a 4.53% decline. This is in contrast...
NYSE:ESAB
NYSE:ESABMachinery

How ESAB’s Mixed Q4, New Dividend and Welding Launch Could Impact ESAB (ESAB) Investors

ESAB Corporation recently reported fourth-quarter 2025 results showing higher sales but lower earnings year-on-year, while its Board affirmed a quarterly cash dividend of US$0.10 per share payable on April 17, 2026. Alongside this, increased institutional ownership and the launch of the Ruffian EMP 270G welding generator signal growing interest in ESAB’s product portfolio and income-return profile. With ESAB maintaining its dividend and enhancing its welding offering, we’ll now examine how...
NYSE:AER
NYSE:AERTrade Distributors

Did Record Results, Bigger Buybacks And Dividends Just Shift AerCap Holdings' (AER) Investment Narrative?

AerCap Holdings recently reported record quarterly net income and earnings per share, announced a new US$1.00 billion share repurchase program, and raised its 2026 quarterly dividend following strong full-year results. These moves, alongside a sharp increase in earnings guidance and growing institutional interest, highlight management’s confidence in AerCap’s cash generation and its emphasis on returning capital to shareholders. With AerCap’s sharply higher EPS guidance and larger dividend...
NasdaqGS:VC
NasdaqGS:VCAuto Components

A Look At Visteon (VC) Valuation After Softer 2025 Earnings And Updated 2026 Sales Guidance

Visteon (VC) just packed several updates into its latest report, combining softer 2025 earnings, fresh 2026 sales guidance of US$3.625b to US$3.825b, a higher dividend, and a completed share repurchase program. See our latest analysis for Visteon. The latest report came with a sharp 3.1% one day share price decline and the stock now trades at US$95.67. However, a 14.3% one year total shareholder return contrasts with weaker three and five year total returns, hinting at recovering but...
NYSE:SFBS
NYSE:SFBSBanks

A Look At ServisFirst Bancshares (SFBS) Valuation After Its 2025 10 K And Growth Outlook Update

What the latest 10-K and conference focus tell you about ServisFirst ServisFirst Bancshares (SFBS) recently filed its 2025 Form 10-K and featured at the 2026 Banking Outlook Conference, putting its capital strength, loan and deposit growth plans, and interest rate sensitivities in clear focus for investors. See our latest analysis for ServisFirst Bancshares. At a share price of US$81.01, ServisFirst has given investors a 14.42% 90 day share price return, even though the 1 year total...
NYSE:SSD
NYSE:SSDBuilding

How New Ohio and Tennessee Plants and 50 Products Will Impact Simpson Manufacturing (SSD) Investors

Simpson Manufacturing recently detailed in its 2025 10-K that it has opened new production facilities in Columbus, Ohio, and Gallatin, Tennessee, while launching over 50 new products across wood, mass timber, and concrete construction categories. This combination of expanded in-house manufacturing and a broad wave of product development highlights how Simpson is reshaping its cost base and deepening its role in structural building solutions. Next, we’ll examine how these new Ohio and...
NasdaqCM:MLTX
NasdaqCM:MLTXBiotechs

MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed?

MoonLake Immunotherapeutics recently reported full-year 2025 results showing a wider net loss of US$227.32 million and a basic loss per share of US$3.53, while highlighting progress in developing its lead drug candidate, Sonelokimab (SLK), across several inflammatory disease indications. The company’s latest filings and updates emphasize FDA and EMA engagement, multiple positive late-stage trial readouts, and a planned SLK Biologics License Application submission in the second half of 2026...
NYSE:RMD
NYSE:RMDMedical Equipment

ResMed (RMD) Valuation Check After New Greenwood Distribution Expansion Announcement

ResMed (RMD) is expanding its U.S. footprint with a new distribution center in Greenwood, Indiana, planned to begin operations in 2027. The facility aims to widen North American coverage for its sleep and respiratory care products. See our latest analysis for ResMed. ResMed’s new Greenwood distribution hub comes as the stock has eased slightly in the short term, with a 7 day share price return showing a 1.74% decline, while longer term performance looks steadier, including a 1 year total...
NasdaqGS:ACIW
NasdaqGS:ACIWSoftware

Did ACI’s 2026 Revenue Guidance and New UK Connetic Win Just Shift ACI Worldwide’s (ACIW) Investment Narrative?

In late February 2026, ACI Worldwide reported Q4 2025 revenue of US$481.6 million and full-year revenue of US$1.76 billion, alongside 2026 guidance calling for US$405–US$415 million in Q1 revenue and full-year revenue of US$1.88–US$1.91 billion, implying 7%–9% constant-currency growth. At the same time, ACI highlighted rapid adoption of its cloud-native Connetic platform, including a new UK retail bank deployment unifying major payment rails and AI-driven fraud prevention on a single...
NYSE:INGR
NYSE:INGRFood

Does CEO Zallie’s New Chairman Role And Share Sale Reshape The Bull Case For Ingredion (INGR)?

Ingredion recently reported a softer fourth quarter for fiscal 2025, with revenue down year on year and its third consecutive quarter of net income and EPS declines, while also missing analysts’ EBITDA and adjusted operating income expectations. Soon after these results, President and CEO James P. Zallie was appointed Chairman following the former Chair’s resignation and sold 9,958 shares under a pre-set Rule 10b5-1 plan, sharpening investor attention on the company’s leadership and...
NYSE:VSCO
NYSE:VSCOSpecialty Retail

Assessing Victoria’s Secret (VSCO) Valuation After Fresh Inflation Jitters Hit Consumer Stocks

The latest stronger than expected US Producer Price Index reading has pushed inflation worries back into focus, pressuring apparel names such as Victoria's Secret (VSCO) as investors reassess risks to discretionary consumer spending and earnings resilience. See our latest analysis for Victoria's Secret. That inflation scare comes after a powerful rebound, with a 30 day share price return of 15.02% and a 90 day share price return of 49.39%, while the 1 year total shareholder return of 161.14%...
NasdaqGS:LKFN
NasdaqGS:LKFNBanks

How Strong Q4 Earnings, Dividend Hike, and Insider Buying Will Impact Lakeland Financial (LKFN) Investors

Lakeland Financial’s recent update included fourth-quarter 2025 earnings that topped consensus estimates, a 4% increase to its quarterly cash dividend paid in February 2026, and director Welch M Scott’s purchase of 10,000 common shares in late February. These events, alongside mixed analyst opinions and contrasting insider transactions, highlight a tension between external research views and internal confidence at the company. We’ll now examine how the stronger-than-expected quarterly...
NasdaqGS:IQ
NasdaqGS:IQEntertainment

Reassessing iQIYI (IQ) Valuation After Sustained Share Price Weakness

Setting the scene for iQIYI (NasdaqGS:IQ) iQIYI (NasdaqGS:IQ) has been under pressure recently, with the share price weaker over the month and past 3 months. This has prompted investors to reassess how its current valuation lines up with recent financial results. See our latest analysis for iQIYI. The latest 1 day share price return of a 6.43% decline extends a weaker trend, with the 30 day share price return down 23.08% and the 1 year total shareholder return down 20.79%. This suggests...
NYSE:CVS
NYSE:CVSHealthcare

A Look At CVS Health (CVS) Valuation After Tennessee Bill 2040 And Insurance Business Retrenchment

CVS Health (CVS) is in the spotlight after Tennessee Senate Bill 2040 advanced, threatening to force the closure of all company pharmacies in the state. CVS also plans to scale back Medicare Advantage and exit Obamacare exchanges. See our latest analysis for CVS Health. At a share price of US$79.90, CVS has seen a 7.22% 1 month share price return and a modest 2.94% 3 month share price return. Its 1 year total shareholder return of 27.81% points to stronger longer term momentum as investors...
NYSE:WTTR
NYSE:WTTREnergy Services

Assessing Select Water Solutions (WTTR) Valuation After Secondary Equity Offering And Growth Outlook

Select Water Solutions (WTTR) is back in focus after a US$175 million secondary equity offering and a new shelf registration, moves the company says will fund water infrastructure projects, potential acquisitions, and possible debt repayment. See our latest analysis for Select Water Solutions. The equity raise and new shelf filing come after a period of strong momentum, with a 90 day share price return of 32.33% and a 5 year total shareholder return of 104.63%, even though the share price...
NasdaqGS:ZBRA
NasdaqGS:ZBRAElectronic

Did New AI Lumber Scanning Win Just Shift Zebra Technologies' (ZBRA) Industrial Automation Narrative?

In February 2026, Zebra Technologies announced that EBI Electric is using its AltiZ 3D sensors and Aurora Imaging software to power Inspector T, an AI-enriched lumber scanning solution that boosts measurement precision and helps mills cut waste while optimizing yield from every plank. The Inspector T system’s ability to detect subtle wood defects and recover up to 5% more usable lumber, with potential annual cost savings near US$750,000 per mill, highlights how Zebra’s machine-vision and AI...
NasdaqGM:ARDX
NasdaqGM:ARDXBiotechs

Assessing Ardelyx (ARDX) Valuation After Strong 2025 Results And 2026 Growth Guidance

Earnings and Guidance Put Ardelyx in Focus Ardelyx (ARDX) has drawn fresh attention after reporting full year 2025 results and issuing 2026 revenue guidance that highlights expected growth in IBSRELA and XPHOZAH sales. For investors watching the stock, the combination of higher 2025 revenue, a wider net loss, and specific product level guidance for 2026 sets the stage for reassessing the company’s risk and reward profile. See our latest analysis for Ardelyx. At a share price of US$6.55,...
NYSE:VLO
NYSE:VLOOil and Gas

How Investors May Respond To Valero Energy (VLO) Refinery Idling, Low‑Carbon Pivot And Biofuel Rule Shifts

In recent months, Valero Energy reported quarterly earnings that surpassed consensus expectations, advanced plans to idle its Benicia refinery by April 2026, and outlined increased investments in low‑carbon projects, while facing new US biofuel blending proposals that could raise compliance costs for large refiners. These developments highlight how Valero is reshaping its refining footprint and fuel mix at the same time that shifting regulations directly affect its operating economics. We’ll...